UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 364.

Weller, M; Holland, E C; Hambardzumyan, D (2017). Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. Brain : a journal of neurology, 140(3):e17.

Schneider, H; Szabo, E; Machado, R A C; Broggini-Tenzer, A; Walter, A; Lobell, M; Heldmann, D; Süssmeier, F; Grünewald, S; Weller, M (2017). Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models. Journal of Neurochemistry, 140(1):170-182.

Weller, M (2017). Kein Fortschritt ohne randomisierte, kontrollierte Studien. InFo Neurologie & Psychiatrie, 19(1):17.

Weller, M (2017). Keine Verbesserung von Gesamtüberleben und Lebensqualität versus Standardtherapie. InFo Neurologie & Psychiatrie, 19(1):30.

Weller, M (2017). MAPK-Hemmung eröffnet neue Perspektiven in der Therapie von Neurofibromen. InFo Neurologie & Psychiatrie, 19(5):12.

Weller, M (2017). Routinemäßige Ganzhirnbestrahlung ist nicht gerechtfertigt. InFo Neurologie & Psychiatrie, 19(2):23.

Avila, E K; Chamberlain, M; Schiff, D; Reijneveld, J C; Armstrong, T S; Ruda, R; Wen, P Y; Weller, M; Koekkoek, J A F; Mittal, S; Arakawa, Y; Choucair, A; Gonzalez-Martinez, J; MacDonald, D R; Nishikawa, R; Shah, A; Vecht, C J; Warren, P; van den Bent, M J; DeAngelis, L M (2017). Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 19(1):12-21.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Weiss, T; Weller, M; Roth, P (2016). Immunological effects of chemotherapy and radiotherapy against brain tumors. Expert Review of Anticancer Therapy, 16(10):1087-1094.

Wirsching, H G; Weller, M (2016). The Role of Molecular Diagnostics in the Management of Patients with Gliomas. Current Treatment Options in Oncology, 17(10):51.

Gramatzki, D; Weller, M (2016). Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer, 122(23):3740-3741.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 34(25):3107-3108.

Goldbrunner, Roland; Minniti, G; Preusser, M; Jenkinson, M D; Sallabanda, K; Houdart, E; von Deimling, A; Stavrinou, P; Lefranc, F; Lund-Johansen, M; Moyal, E C; Brandsma, D; Henriksson, R; Soffietti, R; Weller, M (2016). EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncology, 17(9):e383-e391.

Strehlow, F; Bauer, S; Martus, P; Weller, M; Roth, P; Schlegel, U; Seidel, S; Scheibenbogen, C; Korfel, A; Kreher, S (2016). Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. Journal of Neuro-Oncology, 129(1):165-171.

Mangani, D; Weller, M; Seyed Sadr, E; Willscher, E; Seystahl, K; Reifenberger, G; Tabatabai, G; Binder, H; Schneider, H (2016). Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro-Oncology, 18(12):1610-1621.

Schneider, H; Weller, M (2016). Boswellic acid activity against glioblastoma stem-like cells. Oncology Letters, 11(6):4187-4192.

Burgett, M E; Lathia, J D; Roth, P; Nowacki, A S; Galileo, D S; Pugacheva, E; Huang, P; Vasanji, A; Li, M; Byzova, T; Mikkelsen, T; Bao, S; Rich, J N; Weller, M; Gladson, C L (2016). Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells. OncoTarget:43852-43867.

Berger, M; Weller, M (2016). Gliomas. Amsterdam: Elsevier.

Pitter, K L; Tamagno, I; Alikhanyan, K; Hosni-Ahmed, A; Pattwell, S S; Donnola, S; Dai, C; Ozawa, T; Chang, M; Chan, T A; Beal, K; Bishop, A J; Barker, C A; Jones, T S; Hentschel, B; Gorlia, T; Schlegel, U; Stupp, R; Weller, M; Holland, E C; Hambardzumyan, D (2016). Corticosteroids compromise survival in glioblastoma. Brain, 139(Pt 5):1458-1471.

Broetz, D; Weller, M (2016). Physical Therapy for Intervertebral Disk Disease : A Practical Guide to Diagnosis and Treatment. Stuttgart-New York-Delhi-Rio de Janeiro: Thieme.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Szabo, E; Schneider, H; Seystahl, K; Rushing, E J; Herting, F; Weidner, K M; Weller, M (2016). Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro-Oncology, 18(9):1242-1252.

Gulden-Sala, W; Roth, P; Brown, M; Andratschke, N; Weller, M; Stupp, R (2016). Gliome – was ich wissen muss in zehn Fragen. Praxis, 105(6):330-337.

Stojcheva, Nina; Schechtmann, G; Sass, S; Roth, P; Florea, A M; Stefanski, A; Stühler, K; Wolter, M; Müller, N S; Theis, F J; Weller, M; Reifenberger, G; Happold, C (2016). MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. OncoTarget, 7(11):12937-12950.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 34(7):731-739.

Codó, P; Weller, M; Kaulich, K; Schraivogel, D; Silginer, M; Reifenberger, G; Meister, G; Roth, P (2016). Control of glioma cell migration and invasiveness by GDF-15. OncoTarget, 7(7):7732-7746.

Sommerauer, M; Burkhardt, J K; Frontzek, K; Rushing, E; Buck, A; Krayenbuehl, N; Weller, M; Schaefer, N; Kuhn, F P (2016). 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? Neuro-Oncology, 18(7):1021-1027.

Zörner, B; Filli, L; Reuter, K; Kapitza, S; Lörincz, L; Sutter, T; Weller, D; Farkas, M; Easthope, C S; Czaplinski, A; Weller, M; Linnebank, M (2016). Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. Multiple Sclerosis, 22(11):1463-1475.

Weller, M (2016). Akzeleriert nicht unterlegen. InFo Neurologie & Psychiatrie, 18(9):25.

Roelcke, U; Wyss, M T; Nowosielski, M; Rudà, R; Roth, P; Hofer, S; Galldiks, N; Crippa, F; Weller, M; Soffietti, R (2016). Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-Oncology, 18(5):744-751.

Gramatzki, Dorothee; Roth, P; Felsberg, J; Hofer, S; Rushing, E J; Hentschel, B; Westphal, M; Krex, D; Simon, M; Schnell, O; Wick, W; Reifenberger, G; Weller, M (2016). Chemotherapy for intracranial ependymoma in adults. BMC Cancer, 16(1):287.

Lim, M; Weller, M; Chiocca, E A (2016). Current State of Immune-Based Therapies for Glioblastoma. Educational Book, 35:e132-e139.

Esposito, G; Burgunder, J M; Dunlop, J; Gorwood, P; Inamdar, A; Pfister, S M; Pochet, R; van den Bent, M J; Van Hoylandt, N; Weller, M; Westphal, M; Wick, W; Nutt, D (2016). Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. Public Health Genomics, 19(3):170-177.

Wirsching, H G; Galanis, E; Weller, M (2016). Glioblastoma. Handbook of Clinical Neurology, 134:381-397.

Mason, M; Laperriere, N; Wick, W; Reardon, D A; Malmstrom, A; Hovey, E; Weller, M; Perry, J R (2016). Glioblastoma in the elderly: making sense of the evidence. Neuro-Oncology Practice, 3(2):77-86.

Roth, P; Preusser, M; Weller, M (2016). Immunotherapy of Brain Cancer. Oncology Research and Treatment, 39(6):326-334.

Furtner, J; Schöpf, V; Seystahl, K; Le Rhun, E; Rudà, R; Roelcke, U; Koeppen, S; Berghoff, A S; Marosi, C; Clement, P; Faedi, M; Watts, C; Wick, W; Soffietti, R; Weller, M; Preusser, M (2016). Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology, 18(3):401-407.

Spender, L C; Ferguson, G J; Liu, S; Cui, C; Girotti, M R; Sibbet, G; Higgs, E B; Shuttleworth, M K; Hamilton, T; Lorigan, P; Weller, M; Vincent, D F; Sansom, O J; Frame, M; ten Dijke, P; Marais, Richard; Inman, G J (2016). Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. OncoTarget:1-18.

Weller, M (2016). Neue Studien mit homogeneren Patientenpopulationen durchführen. InFo Onkologie, 1:26.

Hundsberger, T; Hottinger, A F; Roelcke, U; Roth, P; Migliorini, D; Dietrich, P Y; Conen, K; Pesce, G; Hermann, E; Pica, A; Gross, M W; Brügge, D; Plasswilm, L; Weller, M; Putora, P M (2016). Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. Journal of Neuro-Oncology, 126(1):175-183.

Weller, M (2016). Stereotaktische Radiochirurgie oder Ganzhirnbestrahlung? InFo Neurologie & Psychiatrie, 18(7-8):30.

Silginer, M; Burghardt, I; Gramatzki, D; Bunse, L; Leske, H; Rushing, E J; Hao, N; Platten, M; Weller, M; Roth, P (2016). The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway. Oncogene, 35(25):3260-3271.

Weller, M (2016). Verbesserte Überlebensraten. InFo Neurologie & Psychiatrie, 18(11):29.

Weller, M (2016). Welches ist die Standardtherapie bei älteren Menschen? InFo Neurologie & Psychiatrie, 18(9):16.

Weller, M (2016). mTOR-Hemmung als Therapiekonzept etabliert. InFo Neurologie & Psychiatrie, 18(3):24.

Roth, P; Keller, A; Hoheisel, J D; Codo, P; Bauer, A S; Backes, C; Leidinger, P; Meese, E; Thiel, E; Korfel, A; Weller, M (2015). Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. European Journal of Cancer, 51(3):382-390.

Preusser, M; Berghoff, A S; Wick, W; Weller, M (2015). Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? Clinical Neuropathology, 34(6):313-321.

Reardon, D A; Weller, M (2015). Dedication: Andrew T. Parsa. Neuro-Oncology, 17 Suppl:vii2.

Nduom, E K; Weller, M; Heimberger, A B (2015). Immunosuppressive mechanisms in glioblastoma. Neuro-Oncology, 17 Suppl:vii9-vii14.

Okada, H; Weller, M; Huang, R; Finocchiaro, G; Gilbert, M R; Wick, W; Ellingson, B M; Hashimoto, N; Pollack, I F; Brandes, Al A; Franceschi, E; Herold-Mende, C; Nayak, L; Panigrahy, A; Pope, W B; Prins, R; Sampson, J H; Wen, P Y; Reardon, D A (2015). Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, 16(15):e534-e542.

Reardon, D A; Weller, M (2015). Introduction. Neuro-Oncology, 17 Suppl:vii1.

Wirsching, H G; Happold, C; Roth, P; Weller, M (2015). Management of diffusely infiltrating glioma in the elderly. Current Opinion in Oncology, 27(6):502-509.

Baron, Ralf; Ferriero, D M; Frisoni, G B; Bettegowda, C; Gokaslan, Z L; Kessler, J A; Vezzani, A; Waxman, S G; Jarius, S; Wildemann, B; Weller, M (2015). Neurology-the next 10 years. Nature Reviews. Neurology, 11(11):658-664.

Weiss, T; Weller, M; Roth, P (2015). Immunotherapy for glioblastoma: concepts and challenges. Current Opinion in Neurology, 28(6):639-646.

Krishnan, S; Szabo, E; Burghardt, I; Frei, K; Tabatabai, G; Weller, M (2015). Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. OncoTarget, 6(26):22480-22495.

Ellingson, B M; Bendszus, M; Boxerman, J; Barboriak, D; Erickson, B J; Smits, M; Nelson, S J; Gerstner, E; Alexander, B; Goldmacher, G; Wick, W; Vogelbaum, M; Weller, M; Galanis, E; Kalpathy-Cramer, J; Shankar, L; Jacobs, P; Pope, W B; Yang, D; Chung, C; Knopp, M V; Cha, S; van den Bent, M J; Chang, S; Yung, W K; Cloughesy, T F; Wen, P Y; Gilbert, M R (2015). Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 17(9):1188-1198.

Berghoff, A S; Kiesel, B; Widhalm, G; Rajky, O; Ricken, G; Wöhrer, A; Dieckmann, K; Filipits, M; Brandstetter, A; Weller, M; Kurscheid, S; Hegi, M E; Zielinski, C C; Marosi, C; Hainfellner, J A; Preusser, M; Wick, W (2015). Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 17(8):1064-1075.

Hoang-Xuan, K; Bessell, E; Bromberg, J; Hottinger, A F; Preusser, M; Rudà, R; Schlegel, U; Siegal, T; Soussain, C; Abacioglu, U; Cassoux, N; Deckert, M; Dirven, C M; Ferreri, A J; Graus, F; Henriksson, R; Herrlinger, U; Taphoorn, M; Soffietti, R; Weller, M (2015). Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, 16(7):e322-332.

Preusser, M; Weller, M (2015). Brain metastasis research: a late awakening. Chinese Clinical Oncolog, 4(2):17.

Roth, P; Weller, M (2015). Management of neoplastic meningitis. Chinese Clinical Oncology, 4(2):26.

Wick, W; Weller, M (2015). Neuroonkologie. Der Nervenarzt, 86(6):671.

Traber, G L; Pangalu, A; Neumann, M; Costa, J; Weller, M; Huna-Baron, R; Landau, K (2015). Malignant optic glioma - the spectrum of disease in a case series. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie, 253(7):1187-1194.

Roth, P; Weller, M (2015). Chemotherapie von Hirntumoren bei Erwachsenen. Der Nervenarzt, 86(4):495-508.

Kreher, S; Jöhrens, K; Strehlow, F; Martus, P; Borowiec, K; Radke, J; Heppner, F; Roth, P; Thiel, E; Pietsch, T; Weller, M; Korfel, A (2015). Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-Oncology, 17(7):1016-1021.

Korfel, A; Thiel, E; Martus, P; Möhle, R; Griesinger, F; Rauch, Mi; Röth, A; Hertenstein, B; Fischer, T; Hundsberger, T; Mergenthaler, H G; Junghanß, C; Birnbaum, T; Fischer, L; Jahnke, K; Herrlinger, U; Roth, P; Bamberg, M; Pietsch, T; Weller, M (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 84(12):1242-1248.

Frei, K; Gramatzki, D; Tritschler, I; Schroeder, J J; Espinoza, L; Rushing, E J; Weller, M (2015). Transforming growth factor-β pathway activity in glioblastoma. OncoTarget, 6(8):5963-5977.

Woernle, C M; Péus, D; Hofer, S; Rushing, E J; Held, U; Bozinov, O; Krayenbühl, N; Weller, M; Regli, L (2015). Efficacy of surgery and further treatment of progressive glioblastoma. World Neurosurgery, 84(2):301-307.

Ulrich, A; Weiler, S; Weller, M; Rordorf, T; Tarnutzer, A A (2015). Cetuximab induced aseptic meningitis. Journal of Clinical Neuroscience, 22(6):1061-1063.

Roth, P; Happold, C; Weller, M (2015). Corticosteroid use in neuro-oncology: an update. Neuro-Oncology Practice, 2(1):6-12.

Lassen, U; Chinot, O L; McBain, C; Mau-Sørensen, M; Larsen, V A; Barrie, M; Roth, P; Krieter, O; Wang, K; Habben, K; Tessier, J; Lahr, A; Weller, M (2015). Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncology, 17(7):1007-1015.

Suchorska, B; Jansen, N L; Linn, J; Kretzschmar, H; Janssen, H; Eigenbrod, S; Simon, M; Pöpperl, G; Kreth, F W; la Fougere, C; Weller, M; Tonn, J C (2015). Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology, 84(7):710-719.

Reuss, D E; Sahm, F; Schrimpf, D; Wiestler, B; Capper, D; Koelsche, C; Schweizer, L; Korshunov, A; Jones, D T W; Hovestadt, V; Mittelbronn, M; Schittenhelm, J; Herold-Mende, C; Unterberg, A; Platten, M; Weller, M; Wick, W; Pfister, S M; von Deimling, A (2015). ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 129(1):133-146.

Kurscheid, S; Bady, P; Sciuscio, D; Samarzija, I; Shay, T; Vassallo, I; Criekinge, W V; Daniel, R T; van den Bent, M J; Marosi, C; Weller, M; Mason, W P; Domany, E; Stupp, R; Delorenzi, M; Hegi, M E (2015). Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 16(1):16.

Seystahl, K; Tritschler, I; Szabo, E; Tabatabai, G; Weller, M (2015). Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. Neuro-Oncology, 17(2):254-265.

Weller, M (2015). Donepezil: Verbesserung der Kognition nach Bestrahlung. Im Focus Onkologie, 18(12):46.

Weller, M (2015). Drei molekulare Marker für fünf Hauptgruppen. Neue Studien mit homogeneren Patientenpopulationen durchführen. INFO Neurologie & Psychiatrie, 17(10):32.

Thon, N; Kunz, M; Lemke, L; Jansen, N L; Eigenbrod, S; Kreth, S; Lutz, J; Egensperger, R; Giese, A; Herms, J; Weller, M; Kretzschmar, H; Tonn, J C; laFougère, C; Kreth, F W (2015). Dynamic (18) F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. International Journal of Cancer, 136(9):2132-2145.

Weller, M; Schlegel, U (2015). Hirntumoren. In: Schwab, S; Schellinger, P; Werner, C; Unterberg, A; Hacke, W. Neuro-Intensiv-Buch. Heidelberg, 609-619.

Wolpert, F; Happold, C; Reifenberger, G; Florea, A M; Deenen, R; Roth, P; Neidert, M C; Lamszus, K; Westphal, M; Weller, M; Eisele, G (2015). Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS ONE, 10(10):e0139603.

Weller, M (2015). Kann Levetiracetam die Überlebenszeit verlängern? Bis zum Vorliegen eindeutiger Daten sollte auf eine Primärprophylaxe verzichtet werden. InFo Onkologie, (7):20.

Weller, M (2015). Keine Unterschiede im Überleben und bei der Lebensqualität? Diese Studie sollte die Therapiestandards nicht wesentlich beeinflussen. INFO Neurologie & Psychiatrie, 17(12):16.

Weller, M (2015). Keine Zukunft für Temozolomid in dieser Indikation. INFO Neurologie & Psychiatrie, 17(1):11.

Seystahl, K; Weller, M (2015). Molekulare Marker werden zunehmend wichtiger Therapieoptionen bei höhergradigen Gliomen. InFo Onkologie und Haematologie:24-27.

Stupp, R; Weller, M (2015). Neuro-Onkologie – eine junge und interdisziplinäre Spezialität. info@onkologie, 5(1):1.

Happold, C; Weller, M (2015). New insights into acquired temozolomide resistance in glioblastoma? Brain, 138(12):3468-3470.

Kreher, S; Strehlow, F; Martus, P; Roth, P; Hertenstein, B; Röth, A; Birnbaum, T; Griesinger, F; Rauch, M; Kanz, L; Thiel, E; Weller, M; Korfel, A (2015). Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Annals of Hematology, 94(3):409-414.

Weller, M (2015). Temozolomid: Keine Radiosensibilisierung bei Brustkrebs mit Hirnmetastasen. Zerebral metastasiertes Mammakarzinom. InFo Onkologie:19.

Weller, M (2015). ZNS-Tumoren. In: Petrasc, S; Ehninger, G. Colloquium Onkologie 20 – Update Hämatologie/Onkologie 2015. München: Lukon, 542-52.

Stupp, R; Picard, M; Weller, M (2014). Does cilengitide deserve another chance?-Authors' reply. Lancet Oncology, 15(13):e585-e586.

Rieger, J; Bähr, O; Maurer, G D; Hattingen, E; Franz, K; Brucker, D; Walenta, S; Kämmerer, U; Coy, J F; Weller, M; Steinbach, J P (2014). ERGO: A pilot study of ketogenic diet in recurrent glioblastoma / Erratum. International Journal of Oncology, 45(6):2605.

Batchelor, T T; Reardon, D A; de Groot, J F; Wick, W; Weller, M (2014). Antiangiogenic therapy for glioblastoma: current status and future prospects. Clinical Cancer Research, 20(22):5612-5619.

Ahmad, M; Frei, K; Willscher, E; Stefanski, A; Kaulich, K; Roth, P; Stühler, K; Reifenberger, G; Binder, H; Weller, M (2014). How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models. Journal of Neuropathology and Experimental Neurology, 73(11):1062-1077.

Roth, P; Weller, M (2014). Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Neuro-Oncology, 16(suppl 8):viii14-viii19.

Codo, P; Weller, M; Meister, G; Szabo, E; Steinle, A; Wolter, M; Reifenberger, G; Roth, P (2014). MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. OncoTarget, 5(17):7651-7662.

Langen, K J; Tonn, J C; Weller, M; Galldiks, N (2014). Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460]. Journal of Neuro-Oncology, 120(3):665-666.

Weller, M; van den Bent, M; Hopkins, K; Tonn, J C; Stupp, R; Falini, A; Cohen-Jonathan-Moyal, E; Frappaz, D; Henriksson, R; Balana, C; Chinot, O; Ram, Z; Reifenberger, G; Soffietti, R; Wick, W (2014). EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, 15(9):e395-e403.

Weller, M (2014). The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. Neuro-Oncology, 16(8):1035-1036.

Wiestler, B; Capper, D; Hovestadt, V; Sill, M; Jones, D T W; Hartmann, C; Felsberg, J; Platten, M; Feiden, W; Keyvani, K; Pfister, S M; Wiestler, O D; Meyermann, R; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M; Wick, W (2014). Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 16(12):1630-1638.

Wiestler, B; Capper, D; Sill, M; Jones, D T W; Hovestadt, V; Sturm, D; Koelsche, C; Bertoni, A; Schweizer, L; Korshunov, A; Weiß, E K; Schliesser, M G; Radbruch, A; Herold-Mende, C; Roth, P; Unterberg, A; Hartmann, C; Pietsch, T; Reifenberger, G; Lichter, P; Radlwimmer, B; Platten, M; Pfister, S M; von Deimling, A; Weller, M; Wick, W (2014). Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 128(4):561-571.

Wick, W; Weller, M; van den Bent, M; Sanson, M; Weiler, M; von Deimling, A; Plass, C; Hegi, M; Platten, M; Reifenberger, G (2014). MGMT testing-the challenges for biomarker-based glioma treatment. Nature Reviews. Neurology, 10(7):372-85.

Bracko, O; Di Pietro, V; Lazzarino, G; Amorini, A M; Tavazzi, B; Artmann, J; Wong, E C; Buxton, R B; Weller, M; Luft, A R; Wegener, S (2014). 3-Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow. Journal of Cerebral Blood Flow and Metabolism, 34(9):1522-1530.

Stupp, R; Weller, M (2014). Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro-Oncology, 16(6):765-767.

Weller, M; Kaulich, K; Hentschel, B; Felsberg, J; Gramatzki, D; Pietsch, T; Simon, M; Westphal, M; Schackert, G; Tonn, J C; von Deimling, A; Davis, T; Weiss, W A; Loeffler, M; Reifenberger, G (2014). Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 134(10):2437-2447.

Haertle, M; Kallweit, U; Weller, M; Linnebank, M (2014). The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases. Journal of Neurology:554-560.

Wolpert, F; Tritschler, I; Steinle, A; Weller, M; Eisele, G (2014). A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology, 16(3):382-391.

Weller, M (2014). Anpassung der Standardtherapie ohne randomisierte Studie. INFO Neurologie & Psychiatrie, 16(12):30.

Tonder, M; Weller, M; Eisele, G; Roth, P (2014). Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. Chemotherapy, 60(5-6):375-378.

Stupp, R; Hegi, M E; Gorlia, T; et al; Kim, C Y; Nabors, L B; Reardon, D A; van den Bent, M J; Hicking, C; Markivskyy, A; Picard, M; Weller, M (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 15(10):1100-1108.

Eisele, G; Wick, A; Eisele, A C; Clément, P M; Tonn, J; Tabatabai, G; Ochsenbein, A; Schlegel, U; Neyns, B; Krex, D; Simon, M; Nikkhah, G; Picard, M; Stupp, R; Wick, W; Weller, M (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 117(1):141-145.

Hundsberger, T; Tonder, M; Hottinger, A; Brügge, D; Roelcke, U; Putora, P M; Stupp, R; Weller, M (2014). Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. Journal of Neuro-Oncology, 118(2):321-328.

Rieger, J; Bähr, O; Maurer, G D; Hattingen, E; Franz, K; Brucker, D; Walenta, S; Kämmerer, U; Coy, J F; Weller, M; Steinbach, J P (2014). ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. International Journal of Oncology, 44(6):1843-1852.

Riehmer, V; Gietzelt, J; Beyer, U; Hentschel, B; Westphal, M; Schackert, G; Sabel, M C; Radlwimmer, B; Pietsch, T; Reifenberger, G; Weller, M; Weber, R G; Loeffler, M (2014). Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. Genes, Chromosomes and Cancer, 53(7):589-605.

Weller, M (2014). Hotspots in Neuro-Oncology. European Association of NeuroOncology Magazine, 4(1):49-50.

Fischer, S; Ronellenfitsch, M W; Thiepold, A L; Harter, P N; Reichert, S; Kögel, D; Paschke, R; Mittelbronn, M; Weller, M; Steinbach, J P; Fulda, S; Bähr, O (2014). Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic Acid. PLoS ONE, 9(4):e94921.

Silginer, M; Weller, M; Ziegler, U; Roth, P (2014). Integrin inhibition promotes atypical anoikis in glioma cells. Cell Death and Disease, 5:e1012.

Happold, C; Roth, P; Silginer, M; Florea, A M; Lamszus, K; Frei, K; Deenen, R; Reifenberger, G; Weller, M (2014). Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Molecular Cancer Therapeutics, 13(4):948-961.

Rossetti, A O; Jeckelmann, S; Novy, J; Roth, P; Weller, M; Stupp, R (2014). Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-Oncology, 16(4):584-588.

Reifenberger, G; Weber, R G; Riehmer, V; Kaulich, K; Willscher, E; Wirth, H; Gietzelt, J; Hentschel, B; Westphal, M; Simon, M; Schackert, G; Schramm, J; Matschke, J; Sabel, M C; Gramatzki, D; Felsberg, J; Hartmann, C; Steinbach, J P; Schlegel, U; Wick, W; Radlwimmer, B; Pietsch, T; Tonn, J C; von Deimling, A; Binder, H; Weller, M; Loeffler, M (2014). Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 135(8):1822-1831.

Blaes, J; Weiler, M; Sahm, F; Hentschel, B; Osswald, M; Czabanka, M; Thomé, C M; Schliesser, M G; Pusch, S; Luger, S; Winkler, F; Radbruch, A; Jugold, M; Simon, M; Steinbach, J P; Schackert, G; Tatagiba, M; Westphal, M; Tonn, J C; Gramatzki, D; Pietsch, T; Hartmann, C; Glimm, H; Vajkoczy, P; von Deimling, A; Platten, M; Weller, M; Wick, W (2014). NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology, 117(1):25-32.

Weller, M; Wick, W (2014). Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. Nature Reviews. Neurology, 10(2):68-70.

Seystahl, K; Weller, M; Bozinov, O; Reimann, R; Rushing, E (2014). Neuropathological characteristics of progression after prolonged response to bevacizumab in multifocal hemangioblastoma. Oncology Research and Treatment, 37(4):209-212.

Weller, M; Soffietti, R; Brada, M (2014). The legend of cytomegalovirus and glioblastoma lives on. Neuro-Oncology, 16(1):166.

Roth, P; Stupp, R; Eisele, G; Weller, M (2014). Treatment of primary CNS lymphoma. Current Treatment Options in Neurology, 16(1):277.

Weller, M (2014). ZNS-Tumoren. In: Petrasch, S; Ehninger, G. Colloquium Onkologie 18 – Update Hämatologie/Onkologie 2014. München: Lukon, 509-20.

Weiler, M; Blaes, J; Pusch, S; Sahm, F; Czabanka, M; Luger, S; Bunse, L; Solecki, G; Eichwald, V; Jugold, M; Hodecker, S; Osswald, M; Meisner, C; Hielscher, T; Rübmann, P; Pfenning, P N; Ronellenfitsch, M; Kempf, T; Schnölzer, M; Abdollahi, A; Lang, F; Bendszus, M; von Deimling, A; Winkler, F; Weller, M; Vajkoczy, P; Platten, M; Wick, W (2014). mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 111(1):409-414.

Berghoff, A S; Kovanda, A K; Melchardt, T; Bartsch, R; Hainfellner, J A; Sipos, B; Schittenhelm, J; Zielinski, C C; Widhalm, G; Dieckmann, K; Weller, M; Goodman, S L; Birner, P; Preusser, M (2014). αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clinical & Experimental Metastasis, 31(7):841-851.

Seidel, C; Hentschel, B; Simon, M; Schnell, O; Heese, O; Tatagiba, M; Krex, D; Reithmeier, T; Kowoll, A; Weller, M; Wick, W (2013). A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. Journal of Neurology, 260:847-855.

Eisele, G; Wolpert, F; Decrey, G; Weller, M (2013). APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. Anticancer Research, 33(9):3563-3571.

Wiestler, B; Capper, D; Holland-Letz, T; Korshunov, A; von Deimling, A; Pfister, S M; Platten, M; Weller, M; Wick, W (2013). ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica:Epubahead of print.

Gulbins, E; Palmada, M; Reichel, M; Lüth, A; Böhmer, C; Amato, D; Müller, C P; Tischbirek, C H; Groemer, T W; Tabatabai, G; Becker, K A; Tripal, P; Staedtler, S; Ackermann, T F; van Brederode, J; Alzheimer, C; Weller, M; Lang, U E; Kleuser, B; Grassme, H; Kornhuber, J (2013). Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nature Medicine, 19(7):934-938.

Roth, P; Wick, W; Weller, M (2013). Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. Current Treatment Options in Oncology, 14(4):505-513.

Weller, M; Yung, W K A (2013). Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro-Oncology, 15(8):971.

Weller, M (2013). Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma? Neuro-Oncology, 15(7):809-810.

Weller, M (2013). Assessing the MGMT status in glioblastoma: one step forward, two steps back? Neuro-Oncology, 15(3):253-254.

Seystahl, K; Wiestler, B; Hundsberger, T; Happold, C; Wick, W; Weller, M; Wick, A (2013). Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. European Neurology, 69(2):95-101.

Spescha, R D; Shi, Y; Wegener, S; Keller, S; Weber, B; Wyss, M M; Lauinger, N; Tabatabai, G; Paneni, F; Cosentino, F; Hock, C; Weller, M; Nitsch, R M; Lüscher, T F; Camici, G G (2013). Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. European Heart Journal, 34(2):96-103.

Stupp, R; Hottinger, A; Hegi, M E; Weller, M (2013). Diagnostik und Therapie von Gliomen. Swiss Medical Forum, 13(22):421-426.

Weller, M (2013). Die Konsequenzen sind im Detail nicht klar. info@onkologie, 7:12.

Goeppert, B; Schmidt, C R; Geiselhart, L; Dutruel, C; Capper, D; Renner, M; Vogel, M N; Zachskorn, C; Zinke, J; Campos, B; Schmezer, P; Popanda, O; Wick, W; Weller, M; Meyermann, R; Schittenhelm, J; Harter, P N; Simon, P; Weichert, W; Schirmacher, P; Plass, C; Mittelbronn, M (2013). Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. Journal of Neuropathology and Experimental Neurology, 72(10):933-941.

Koelsche, C; Sahm, F; Capper, D; Reuss, D; Sturm, D; Jones, D T W; Kool, M; Northcott, P A; Wiestler, B; Böhmer, K; Meyer, J; Mawrin, C; Hartmann, C; Mittelbronn, M; Platten, M; Brokinkel, B; Seiz, M; Herold-Mende, C; Unterberg, A; Schittenhelm, J; Weller, M; Pfister, S; Wick, W; Korshunov, A; von Deimling, A (2013). Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 126(6):907-915.

Weller, M; Stupp, R; Wick, W (2013). Drei negative (?)Phase-III-Studien auf dem ASCO-Kongress 2013. Steht die Angiogenesehemmung beim Glioblastom vor dem Aus? Leading Opinions Hämatologie & Onkologie, 4:52-53.

Fan, Q W; Cheng, C K; Gustafson, W C; Charron, E; Zipper, P; Wong, R A; Chen, J; Lau, J; Knobbe-Thomsen, C; Weller, M; Jura, N; Reifenberger, G; Shokat, K M; Weiss, W A (2013). EGFR Phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell, 24(4):438-449.

Weller, M; Stupp, R (2013). EORTC-EANO-ESMO-Konferenz 2013: die vIII-Mutationsvariante des epidermalen Wachstumsfaktorrezeptors – EGFRvIII als Angriffspunkt für die Immuntherapie des Glioblastoms. Leading Opinions Hämatologie & Onkologie:52-53.

Weller, M (2013). Empfehlung zum Einsatz von Valganciclovir entbehrt jeder Grundlage. INFO Neurologie & Psychiatrie, 15(10):12.

Heese, O; Vogeler, E; Martens, T; Schnell, O; Tonn, J C; Simon, M; Schramm, J; Krex, D; Schackert, G; Reithmeier, T; Nikkhah, G; Sabel, M; Steiger, H J; Schlegel, U; Löffler, M; Weller, M; Westphal, M (2013). End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro-Oncology, 15(9):1251-1256.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; Macdonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2013). Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 126(1):159.

Mittelbronn, M; Warth, A; Meyermann, R; Goodman, S; Weller, M (2013). Expression of integrins αvβ3 and αvβ5 and their ligands in primary and secondary central nervous system neoplasms. Histology and Histopathology, 28(6):749-758.

Gramatzki, D; Herrmann, C; Happold, C; Becker, K A; Gulbins, E; Weller, M; Tabatabai, G (2013). Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS ONE, 8(5):e63527.

Kreth, F W; Thon, N; Simon, M; Westphal, M; Schackert, G; Nikkhah, G; Hentschel, B; Reifenberger, G; Pietsch, T; Weller, M; Tonn, J C (2013). Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Annals of Oncology, 24(12):3117-3123.

Gonzenbach, R R; Kong, Y; Beck, B; Buck, A; Weller, M; Semmler, A (2013). High-dose praziquantel therapy for cerebral sparganosis. Journal of Neurology, 260(5):1423-1425.

Weller, M (2013). Hotspots in Neuro-Oncology. European Association of NeuroOncology Magazine, 3(2):84-85.

Weller, M (2013). Hotspots in Neuro-Oncology. European Association of NeuroOncology Magazine, 3(1):37.

Roth, P; Silginer, M; Goodman, S L; Hasenbach, K; Thies, S; Maurer, G; Schraml, P; Tabatabai, G; Moch, H; Tritschler, I; Weller, M (2013). Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain, 136(2):564-576.

Berghoff, A S; Rajky, O; Winkler, F; Bartsch, R; Furtner, J; Hainfellner, J A; Goodman, S L; Weller, M; Schittenhelm, J; Preusser, M (2013). Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 15(12):1664-1672.

Schippling, S; Kempf, C; Büchele, F; Jelcic, I; Bozinov, O; Bont, A; Linnebank, M; Sospedra, M; Weller, M; Budka, H; Martin, R (2013). JCV granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Annals of Neurology, 74(4):622-626.

Hartmann, C; Hentschel, B; Simon, M; Westphal, M; Schackert, G; Tonn, J C; Loeffler, M; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M (2013). Longterm survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clinical Cancer Research, 19(18):5146-5157.

Wiestler, B; Claus, R; Hartlieb, S A; Schliesser, M G; Weiss, E K; Hielscher, T; Platten, M; Dittmann, L M; Meisner, C; Felsberg, J; Happold, C; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Grimm, C; Weichenhan, D; Tews, B; Reifenberger, G; Capper, D; Müller, W; Plass, C; Weller, M; Wick, W (2013). Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 15(8):1017-1026.

Weller, M; Pfister, S M; Wick, W; Hegi, M E; Reifenberger, G; Stupp, R (2013). Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, 14(9):e370-e379.

Schreglmann, S R; Jelčić, I; Taegtmeyer, A B; Linnebank, M; Weller, M (2013). Multifocal CNS demyelination after octreotide treatment for metastatic meningioma. Clinical Neurology and Neurosurgery, 115(6):817-819.

Laperriere, N; Weller, M; Stupp, R; Perry, J R; Brandes, A A; Wick, W; van den Bent, M J (2013). Optimal management of elderly patients with glioblastoma. Cancer Treatment Reviews, 39(4):350-357.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

Riemenschneider, M J; Louis, D N; Weller, M; Hau, P (2013). Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. Acta Neuropathologica, 126(1):21-37.

Weller, M; Cloughesy, T; Perry, J R; Wick, W (2013). Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro-Oncology, 15(1):4-27.

Weiler, M; Pfenning, P N; Thiepold, A L; Blaes, J; Jestaedt, L; Gronych, J; Dittmann, L M; Berger, B; Jugold, M; Kosch, M; Combs, S E; von Deimling, A; Weller, M; Bendszus, M; Platten, M; Wick, W (2013). Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene, 32(9):1099-1109.

Eisele, G; Weller, M (2013). Targeting apoptosis pathways in glioblastoma. Cancer Letters, 332(2):335-345.

Maercker, Andreas; Perkonigg, A; Preisig, M; Schaller, K; Weller, M (2013). The costs of disorders of the brain in Switzerland: an update from the European Brain Council Study for 2010. Swiss Medical Weekly, 143:online.

Wegener, S; Artmann, J; Luft, A R; Buxton, R B; Weller, M; Wong, E C (2013). The time of maximum post-ischemic hyperperfusion indicates infarct growth following transient experimental ischemia. PLoS ONE, 8(5):e65322.

Roth, P; Regli, L; Tonder, M; Weller, M (2013). Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Review of Anticancer Therapy, 13(11):1319-1325.

Weller, M (2013). Überlegenheit ist hier schwierig zu zeigen. INFO Neurologie & Psychiatrie, 15(11):33.

Vogetseder, A; Thies, S; Ingold, B; Roth, P; Weller, M; Schraml, P; Goodman, S L; Moch, H (2013). αv-Integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 133(10):2362-2371.

Capper, D; Simon, M; Langhans, C D; Okun, J G; Tonn, J C; Weller, M; von Deimling, A; Hartmann, C (2012). 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. International Journal of Cancer, 131(3):766-768.

Riklin, C; Seystahl, K; Hofer, S; Happold, C; Winterhalder, R; Weller, M (2012). Antiangiogenic treatment for multiple CNS hemangioblastomas. Onkologie, 35(7-8):443-445.

Linnebank, M; Moskau, S; Semmler, A; Widman, G; Weller, M; Kallweit, U; Elger, C E (2012). Antiepileptic drugs and vitamin B6 plasma levels in adult patients. Epilepsy Research, 101(1-2):182-184.

Brandes, A A; Franceschi, E; Gorlia, T; Wick, W; Jacobs, A H; Baumert, B G; van den Bent, M; Weller, M; Stupp, R (2012). Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. European Journal of Cancer, 48(6):896-903.

Petersen, J A; Jung, H H; Weller, M; Linnebank, M (2012). Autoimmune myasthenia gravis after sternal fracture. Case Reports in Neurology, 4(1):20-22.

Attia, A; Tatter, S B; Weller, M; Marshall, K; Lovato, J F; Bourland, J D; Ellis, T L; McMullen, K P; Shaw, E G; Chan, M D (2012). CT-only planning for Gamma Knife radiosurgery in the treatment of trigeminal neuralgia: methodology and outcomes from a single institution. Journal of Medical Imaging and Radiation Oncology, 56(4):490-494.

Tabatabai, G; Hegi, M; Stupp, R; Weller, M (2012). Clinical implications of molecular neuropathology and biomarkers for malignant glioma. Current Neurology and Neuroscience Reports, 12(3):302-307.

Zorina, O I; Haueis, P; Semmler, A; Marti, I; Gonzenbach, R R; Guzek, M; Kullak-Ublick, G A; Weller, M; Russmann, S (2012). Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. Pharmacoepidemiology and Drug Safety, 21(8):872-880.

Lemke, D; Pfenning, P N; Sahm, F; Klein, A C; Kempf, T; Warnken, U; Schnölzer, M; Tudoran, R; Weller, M; Platten, M; Wick, W (2012). Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clinical Cancer Research, 18(1):105-117.

Happold, C; Roth, P; Wick, W; Schmidt, N; Florea, A M; Silginer, M; Reifenberger, G; Weller, M (2012). Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 122(2):444-455.

Taegtmeyer, A B; Curkovic, I; Corti, N; Rosen, C; Egbring, M; Russmann, S; Gantenbein, A R; Weller, M; Kullak-Ublick, G A (2012). Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients. Swiss Medical Weekly, 142:w13615.

Wick, W; Weller, M (2012). Elderly people with glioblastoma - Authors' reply. Lancet Oncology, 13(8):e329.

Hegi, M E; Rajakannu, P; Weller, M (2012). Epidermal growth factor receptor: a re-emerging target in glioblastoma. Current Opinion in Neurology, 25(6):774-779.

Weller, M; Stupp, R; Wick, W (2012). Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncology, 13(9):e375-e382.

Wolpert, F; Roth, P; Lamszus, K; Tabatabai, G; Weller, M; Eisele, G (2012). HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. Journal of Neuroimmunology, 250(1-2):27-34.

Wick, W; Winkler, F; Westphal, M; Weller, M (2012). Hirnmetastasen. In: Brandt, T; Diener, H C; Gerloff, C. Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer, 862-877.

Weller, M (2012). Hotspots in Neuro-Oncology. European Association of NeuroOncology Magazine, 2(1):57.

Weller, M (2012). Hotspots in Neuro-Oncology. European Association of NeuroOncology Magazine, 2(2):109.

Weller, M (2012). Hotspots in Neuro-Oncology. European Association of NeuroOncology Magazine, 2(3):149.

Roth, P; Eisele, G; Weller, M (2012). Immunology of brain tumors. In: Aminoff, M; Boller, F; Swaab, D. Neuro-Oncology. Amsterdam: Elsevier, 45-51.

Weller, M; Stupp, R; Hegi, M; Wick, W (2012). Individualized targeted therapy for glioblastoma: fact or fiction? Cancer Journal, 18(1):40-44.

Bähr, O; Hermisson, M; Rona, S; Rieger, J; Nussbaumer, S; Körtvelyessy, P; Franz, K; Tatagiba, M; Seifert, V; Weller, M; Steinbach, J P (2012). Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochirurgica, 154(2):229-235.

Seystahl, K; Weller, M (2012). Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opinion on Investigational Drugs, 21(5):605-617.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; McDonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 124(4):547-560.

Essig, M; Anzalone, N; Combs, S E; Dörfler, A; Lee, S K; Picozzi, P; Rovira, A; Weller, M; Law, M (2012). MR imaging of neoplastic central nervous system lesions: Review and recommendations for current practice. American Journal of Neuroradiology, 33(5):803-817.

Weller, M (2012). Management of gliomas: relevance of molecular markers for clinical practice. European Association of NeuroOncology Magazine, 2(1):6-10.

Wick, W; Weller, M (2012). Meningeosis neoplastica. In: Brandt, T; Diener, H C; Gerloff, C. Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer, 878-886.

Weller, M (2012). Microglia: a novel treatment target in gliomas. Neuro-Oncology, 14(8):957.

Hasenbach, K; Wiehr, S; Herrmann, C; Mannheim, J; Cay, F; von Kürthy, G; Bolmont, T; Grathwohl, S A; Weller, M; Lengerke, C; Pichler, B J; Tabatabai, G (2012). Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. Neuro-oncology, 14(4):471-481.

Weller, M (2012). More on the immune privilege of glioblastoma. Neuro-Oncology, 14(5):527-528.

Roth, P; Martus, P; Kiewe, P; Mohle, R; Klasen, H; Rauch, M; Roth, A; Kaun, S; Thiel, E; Korfel, A; Weller, M (2012). Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology, 79(9):890-896.

Burger, M C; Brucker, D P; Baumgarten, P; Ronellenfitsch, M W; Wanka, C; Hasselblatt, M; Eccles, M R; Klingebiel, T; Weller, M; Rieger, J; Mittelbronn, M; Steinbach, J P (2012). PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. International Journal of Oncology, 41(1):235-241.

Roth, P; Korfel, A; Martus, P; Weller, M (2012). Pathogenesis and management of primary CNS lymphoma. Expert Review of Anticancer Therapy, 12(5):623-633.

Weller, M; Stupp, R; Hegi, M E; van den Bent, M; Tonn, J C; Sanson, M; Wick, W; Reifenberger, G (2012). Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 14(Suppl. 4):iv100-iv108.

Galanis, E; Wu, W; Cloughesy, T; Lamborn, K; Mann, B; Wen, P Y; Reardon, D A; Wick, W; Macdonald, D; Armstrong, T S; Weller, M; Vogelbaum, M; Colman, H; Sargent, D J; van den Bent, M J; Gilbert, M; Chang, S (2012). Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, 13(5):e196-e204.

Reifenberger, G; Hentschel, B; Felsberg, J; Schackert, G; Simon, M; Schnell, O; Westphal, M; Wick, W; Pietsch, T; Loeffler, M; Weller, M (2012). Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. International Journal of Cancer, 131(6):1342-1350.

Hegi, M E; Janzer, R C; Lambiv, W L; Gorlia, T; Kouwenhoven, M C M; Hartmann, C; von Deimling, A; Martinet, D; Besuchet Schmutz, N; Diserens, A C; Hamou, M F; Bady, P; Weller, M; van den Bent, M J; Mason, W P; Mirimanoff, R O; Stupp, R; Mokhtari, K; Wesseling, P (2012). Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 123(6):841-852.

Weller, M; Stupp, R (2012). Prime time for molecular marker diagnostics in neuro-oncology. Current Opinion in Neurology, 25(6):743-744.

Wick, W; Tonn, J C; Weller, M (2012). Primäre intrakranielle und spinale Tumoren. In: Brandt, T; Diener, H S; Gerloff, C. Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer, 813-847.

Korfel, A; Weller, M; Martus, P; Roth, P; Klasen, H A; Roeth, A; Rauch, M; Hertenstein, B; Fischer, T; Hundsberger, T; Leithäuser, M; Birnbaum, T; Kirchen, H; Mergenthaler, H G; Schubert, J; Berdel, W; Birkmann, J; Hummel, M; Thiel, E; Fischer, L (2012). Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Annals of Oncology, 23(9):2374-2380.

Christians, A; Hartmann, C; Benner, A; Meyer, J; von Deimling, A; Weller, M; Wick, W; Weiler, M (2012). Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE, 7(3):e33449.

Wienecke, M; Werth, E; Poryazova, R; Baumann-Vogel, H; Bassetti, C L; Weller, M; Waldvogel, D; Storch, A; Baumann, C R (2012). Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? Journal of Sleep Research, 21(6):710-717.

Weller, M; Martus, P; Roth, P; Thiel, E; Korfel, A (2012). Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology, 14(12):1481-1484.

Kallweit, U; Jelcic, I; Braun, N; Fischer, H; Zörner, B; Schreiner, B; Sokolov, A A; Martin, R; Weller, M; Linnebank, M (2012). Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clinical Neuropharmacology, 35(2):77-80.

Wanka, C; Brucker, D P; Bähr, O; Ronellenfitsch, M; Weller, M; Steinbach, J P; Rieger, J (2012). Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene, 31(33):3764-3776.

Wick, W; Platten, M; Meisner, C; Felsberg, J; Tabatabai, G; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Combs, S E; Vesper, J; Braun, C; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; Reifenberger, G; Weller, M (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7):707-715.

Weller, M (2012). ZNS-Tumoren. In: Petrasch, S; Ehninger, G. Colloquium Onkologie 14 – Update Hämatologie/Onkologie 2012. München: Lukon, 485-95.

Kühnlein, P; Jung, H H; Farkas, M; Keskitalo, S; Ineichen, B; Jelcic, I; Petersen, J; Semmler, A; Weller, M; Ludolph, A C; Linnebank, M (2011). The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is a possible risk factor for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 12(2):136-139.

Eisele, G; Roth, P; Hasenbach, K; Aulwurm, S; Wolpert, F; Tabatabai, G; Wick, W; Weller, M (2011). APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-Oncology, 13(2):155-164.

Linnebank, M; Moskau, S; Semmler, A; Widman, G; Stoffel-Wagner, B; Weller, M; Elger, C E (2011). Antiepileptic drugs interact with folate and vitamin B12 serum levels. Annals of Neurology, 69(2):352-359.

Weller, M; Wick, W (2011). "Nanomania" ante portas of neurooncology? Journal of Neuro-Oncology, 104(2):613-614.

Roth, P; Wischhusen, J; Happold, C; Chandran, P A; Hofer, S; Eisele, G; Weller, M; Keller, A (2011). A specific miRNA signature in the peripheral blood of glioblastoma patients. Journal of Neurochemistry, 118(3):449-457.

Opitz, C A; Litzenburger, U M; Sahm, F; Ott, M; Tritschler, I; Trump, S; Schumacher, T; Jestaedt, L; Schrenk, D; Weller, M; Jugold, M; Guillemin, G J; Miller, C L; Lutz, C; Radlwimmer, B; Lehmann, I; von Deimling, A; Wick, W; Platten, M (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 478(7368):197-203.

Weller, M; Wick, W (2011). Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma? Neuro-Oncology, 13(4):365-366.

Wick, A; Dörner, N; Schäfer, N; Hofer, S; Heiland, S; Schemmer, D; Platten, M; Weller, M; Bendszus, M; Wick, W (2011). Bevacizumab does not increase the risk of remote relapse in malignant glioma. Annals of Neurology, 69(3):586-592.

Schraivogel, D; Weinmann, L; Beier, D; Tabatabai, G; Eichner, A; Zhu, J Y; Anton, M; Sixt, M; Weller, M; Beier, C P; Meister, G (2011). CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. The EMBO Journal, 30(20):4309-4322.

Schittenhelm, J; Simon, P; Harter, P N; Zachskorn, C; Schlaszus, H; Röttger, F; Winkels, M; Weller, M; Meyermann, R; Mittelbronn, M (2011). CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms. Histopathology, 58(5):739-749.

Reardon, D A; Neyns, B; Weller, M; Tonn, J C; Nabors, L B; Stupp, R (2011). Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncology, 7(3):339-354.

Hofer, S; Elandt, K; Greil, R; Hottinger, A F; Huber, U; Lemke, D; Marosi, C; Ochsenbein, A; Pichler, J; Roelcke, U; Weder, P; Zander, T; Wick, W; Weller, M (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncologica, 50(5):630-635.

Weller, M; Stupp, R (2011). Clinical trials in neuro-oncology: one step forward, two steps back? Current Opinion in Neurology, 24(6):597-598.

Preusser, M; de Ribaupierre, S; Wöhrer, A; Erridge, S C; Hegi, M; Weller, M; Stupp, R (2011). Current concepts and management of glioblastoma. Annals of Neurology, 70(1):9-21.

Grauer, O; Pascher, C; Hartmann, C; Zeman, F; Weller, M; Proescholdt, M; Brawanski, A; Pietsch, T; Wick, W; Bogdahn, U; Hau, P (2011). Erratum to: Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). Journal of Neuro-Oncology, 105(3):671.

Guzek, M; Zorina, O I; Semmler, A; Gonzenbach, R R; Huber, M; Kullak-Ublick, G A; Weller, M; Russmann, S (2011). Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System). Pharmacoepidemiology and Drug Safety, 20(9):930-938.

Weller, M; Platten, M; Roth, P; Wick, W (2011). Geriatric neuro-oncology: from mythology to biology. Current Opinion in Neurology, 24(6):599-604.

Tabatabai, G; Weller, M (2011). Glioblastoma stem cells. Cell and Tissue Research, 343(3):459-465.

Schackert, G; Pinzer, T; Kortmann, R D; Weller, M (2011). Hirntumoren. In: Schlag, P M; Bamberg, M; Jäger, D. Interdisziplinäre Entscheidungswege in der Onkologie. Köln: Deutscher Ärzte-Verlag, 41-47.

Weller, M (2011). Hotspots in Neuro-Oncology. European Association of NeuroOncology Magazine, 1(1):59.

Weller, M; Wick, W; von Deimling, A (2011). Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia, 59(8):1200-1204.

Mittelbronn, M; Platten, M; Zeiner, P; Dombrowski, Y; Franke, B; Zachskorn, C; Harter, P N; Weller, M; Wischhusen, J (2011). Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathologica, 122(3):353-365.

Hartmann, C; Hentschel, B; Tatagiba, M; Schramm, J; Schnell, O; Seidel, C; Stein, R; Reifenberger, G; Pietsch, T; von Deimling, A; Loeffler, M; Weller, M (2011). Molecular markers in low-grade gliomas: predictive or prognostic? Clinical Cancer Research, 17(13):4588-4599.

Glas, M; Bähr, O; Felsberg, J; Rasch, K; Wiewrodt, D; Schabet, M; Simon, M; Urbach, H; Steinbach, J P; Rieger, J; Fimmers, R; Bamberg, M; Nägele, T; Reifenberger, G; Weller, M; Herrlinger, U (2011). NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology, 70(3):445-53.

Weller, M (2011). Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials. Neuro-Oncology, 13(6):565.

Weller, M (2011). Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Medical Weekly, 141:w13210.

Perry, J R; Wick, W; Weller, M (2011). Optimizing the use of alkylators in neuro-oncology. Educational Book, 2001:61-64.

Wick, W; Weller, M; Weiler, M; Batchelor, T; Yung, A W; Platten, M (2011). Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology, 13(6):566-579.

Wick, W; Wick, A; Weiler, M; Weller, M (2011). Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Current Neurology and Neuroscience Reports, 11(3):305-312.

Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.

Felsberg, J; Thon, N; Eigenbrod, S; Hentschel, B; Sabel, M C; Westphal, M; Schackert, G; Kreth, F W; Pietsch, T; Löffler, M; Weller, M; Reifenberger, G; Tonn, J C (2011). Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. International Journal of Cancer, 129(3):659-670.

Tabatabai, G; Wick, W; Weller, M (2011). Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? Discovery medicine, 11(61):529-536.

Grauer, O; Pascher, C; Hartmann, C; Zeman, F; Weller, M; Proescholdt, M; Brawanski, A; Pietsch, T; Wick, W; Bogdahn, U; Hau, P (2011). Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). Journal of Neuro-Oncology, 104(3):801-809.

Tabatabai, G; Tonn, J C; Stupp, R; Weller, M (2011). The role of integrins in glioma biology and anti-glioma therapies. Current Pharmaceutical Design, 17(23):2402-2410.

Wick, W; Weller, M (2011). Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). Neuro-Oncology, 13(5):559-560; author reply 561.

Weller, M (2011). ZNS-Tumoren. In: Petrasch, S; Ehninger, G. Update Hämatologie/Onkologie 2011. München: Lukon, 509-529.

Wick, W; Weller, M (2010). Strukturen neuroonkologischer Wissenschaft und Versorgung. Der Nervenarzt, 81(8):911-912.

Weiler, M; Hartmann, C; Wiewrodt, D; Herrlinger, U; Gorlia, T; Bähr, O; Meyermann, R; Bamberg, M; Tatagiba, M; von Deimling, A; Weller, M; Wick, W (2010). Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. International Journal of Radiation Oncology, Biology and Physics, 77(3):670-676.

Roth, P; Junker, M; Tritschler, I; Mittelbronn, M; Dombrowski, Y; Breit, S N; Tabatabai, G; Wick, W; Weller, M; Wischhusen, J (2010). GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clinical Cancer Research, 16(5):3851-3859.

Brötz, D; Maschke, E; Burkard, S; Engel, C; Mänz, C; Ernemann, U; Wick, W; Weller, M (2010). Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica? Pain, 149(3):470-475.

Lanz, T; Opitz, C; Ho, P; Agrawal, A; Lutz, C; Weller, M; Mellor, A; Steinman, L; Wick, W; Platten, M (2010). Mouse mesenchymal stem cells suppress antigen-specific TH-cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells and Development, 19(5):657-668.

Kurzwelly, D; Glas, M; Roth, P; Weimann, E; Lohner, H; Waha, A; Schabet, M; Reifenberger, G; Weller, M; Herrlinger, U (2010). Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 97(3):389-392.

Weller, M (2010). Immunotherapy for glioblastoma: a long and winding road. Neuro-Oncology, 12(4):319.

Zieker, D; Königsrainer, I; Tritschler, I; Löffler, M; Beckert, S; Traub, F; Nieselt, K; Bühler, S; Weller, M; Gaedcke, J; Taichman, R S; Northoff, H; Brücher, B L; Königsrainer, A (2010). Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. International Journal of Cancer, 126(6):1513-1520.

Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology, 12(3):219-220.

Wick, W; Weller, M; van den Bent, M; Stupp, R (2010). Bevacizumab and recurrent malignant gliomas: a European perspective. Journal of Clinical Oncology, 28(12):e188-e189; author reply e190.

Dresemann, G; Weller, M; Rosenthal, M A; Wedding, U; Wagner, W; Engel, E; Heinrich, B; Mayer-Steinacker, R; Karup-Hansen, A; Fluge, O; Nowak, A; Mehdorn, M; Schleyer, E; Krex, D; Olver, I N; Steinbach, J P; Hosius, C; Sieder, C; Sorenson, G; Parker, R; Nikolova, Z (2010). Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of Neuro-Oncology, 96(3):393-402.

Klotz, L; Farkas, M; Bain, N; Keskitalo, S; Semmler, A; Ineichen, B; Jelcic, J; Klockgether, T; Kösch, H; Weller, M; Linnebank, M (2010). The variant methylenetetrahydrofolate reductase c.1298A > C (p.E429A) is associated with multiple sclerosis in a German case-control study. Neuroscience Letters, 468(3):183-185.

Stupp, R; Weller, M (2010). 2010: neuro-oncology is moving! Current Opinion in Neurology, 23(6):553-555.

Wick, W; Weller, M (2010). Anaplastische Gliome: Neuropathologie, molekulare Diagnostik und aktuelle Studienkonzepte. Der Nervenarzt, 81(8):928-935.

Weller, M (2010). Angiogenesis in glioblastoma: just another moving target? Brain: A Journal of Neurology, 133(4):955-956.

Hofer, S; Linnebank, M; Weller, M; Bahmanyar, S; Montgomery, S M; Hillert, J; Ekbom, A; Olsson, T (2010). Cancer risk among patients with multiple sclerosis and their parents. Neurology, 74(7):614-615; author reply 615.

Weller, M (2010). Chemotherapy for low-grade gliomas: when? how? how long? Neuro-Oncology, 12(10):1013.

Heese, O; Schmidt, M; Nickel, S; Berger, H; Goldbrunner, R; Tonn, J C; Bhär, O; Steinbach, J P; Simon, M; Schramm, J; Krex, D; Schackert, G; Reithmeier, T; Nikkhah, G; Löffler, M; Weller, M; Westphal, M (2010). Complementary therapy use in patients with glioma: an observational study. Neurology, 75(24):2229-2235.

Berger, B; Capper, D; Lemke, D; Pfenning, P N; Platten, M; Weller, M; von Deimling, A; Wick, W; Weiler, M (2010). Defective p53 antiangiogenic signaling in glioblastoma. Neuro-Oncology, 12(9):894-907.

Valko, P O; Waldvogel, D; Weller, M; Bassetti, C L; Held, U; Baumann, C R (2010). Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. European Journal of Neurology, 17(12):1428-1436.

Jung, H H; Bremer, J; Weller, M (2010). Gene therapy for myositis. In: Chernajovsky, Y; Robbins, P D. Gene therapy for autoimmune and inflammatory. Basel: Birkhäuser, 79-90.

Kurzwelly, D; Knop, S; Guenther, M; Loeffler, J; Korfel, A; Thiel, E; Hebart, H; Simon, M; Weller, M; Linnebank, M; Herrlinger, U (2010). Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population. Journal of Neuro-Oncology, 100(2):187-192.

Temme, A; Geiger, K D; Wiedemuth, R; Conseur, K; Pietsch, T; Felsberg, J; Reifenberger, G; Tatsuka, M; Hagel, C; Westphal, M; Berger, H; Simon, M; Weller, M; Schackert, G (2010). Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. Journal of Neuropathology and Experimental Neurology, 69(6):632-642.

Tabatabai, G; Hasenbach, K; Herrmann, C; Maurer, G; Möhle, R; Marini, P; Grez, M; Wick, W; Weller, M (2010). Glioma tropism of lentivirally transduced hematopoietic progenitor cells. International Journal of Oncology, 36(6):1409-1417.

Thiel, E; Korfel, A; Martus, P; Kanz, L; Griesinger, F; Rauch, M; Roth, A; Hertenstein, B; von Toll, T; Hundsberger, T; Mergenthaler, H G; Leithäuser, M; Birnbaum, T; Fischer, L; Jahnke, K; Herrlinger, U; Plasswilm, L; Nägele, T; Pietsch, T; Bamberg, M; Weller, M (2010). High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncology, 11(11):1036-1047.

Maurer, G D; Schittenhelm, J; Ernemann, U; Kempf, V A J; Ritz, R; Weller, M; Schmidt, F (2010). Intracranial hemangiomas in a patient with POEMS syndrome. Journal of Neurology, 257(3):484-487.

Weller, M; Stupp, R; Reifenberger, G; Brandes, A A; van den Bent, M J; Wick, W; Hegi, M E (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Reviews. Neurology, 6(1):39-51.

Tabatabai, G; Stupp, R; van den Bent, M J; Hegi, M E; Tonn, J C; Wick, W; Weller, M (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 120(5):585-592.

Weller, M; Wick, W (2010). Nanotechnologie in der Neuroonkologie: Eine Herausforderung für die evidenzbasierte Medizin. Aktuelle Neurologie, 37(8):382-383.

Stupp, R; Hegi, M; Weller, M (2010). Neuro-oncology, a decade of temozolomide and beyond. Expert Review of Anticancer Therapy, 10(11):1675-1677.

Hofer, S; Happold, C; Weller, M (2010). Oligodendroglioma. In: Tonn, J C; Westphal, M; Rutka, J T. Oncology of CNS Tumors. Berlin, Heidelberg : Springer, 163-170.

Wegener, S; Bremer, J; Komminoth, P; Jung, H H; Weller, M (2010). Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. Case Reports in Oncology, 3(1):88-92.

Hartmann, C; Hentschel, B; Wick, W; Capper, D; Felsberg, J; Simon, M; Westphal, M; Schackert, G; Meyermann, R; Pietsch, T; Reifenberger, G; Weller, M; Loeffler, M; von Deimling, A (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 120(6):707-718.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 28(16):2712-2718.

Wick, W; Puduvalli, V K; Chamberlain, M C; van den Bent, M J; Carpentier, A F; Cher, L M; Mason, W; Weller, M; Hong, S; Musib, L; Liepa, A M; Thornton, D E; Fine, H A (2010). Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. Journal of Clinical Oncology, 28(7):1168-1174.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M J; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Reply to M.C. Chamberlain. Journal of Clinical Oncology, 28(33):e696-e697.

Linnebank, M; Popp, J; Smulders, Y; Smith, D; Semmler, A; Farkas, M; Kulic, L; Cvetanovska, G; Blom, H; Stoffel-Wagner, B; Kölsch, H; Weller, M; Jessen, F (2010). S-Adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. Neurodegenerative Diseases, 7(6):373-378.

Weller, M; Wick, W; Hegi, M E; Stupp, R; Tabatabai, G (2010). Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncology, 6(9):1407-1414.

Miller, J; Eisele, G; Tabatabai, G; Aulwurm, S; von Kürthy, G; Stitz, L; Roth, P; Weller, M (2010). Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. Journal of Neurosurgery, 113(2):280-285.

Roth, P; Wick, W; Weller, M (2010). Steroids in neurooncology: actions, indications, side-effects. Current Opinion in Neurology, 23(6):597-602.

Tabatabai, G; Weller, M; Nabors, B; Picard, M; Reardon, D; Mikkelsen, T; Ruegg, C; Stupp, R (2010). Targeting integrins in malignant glioma. Targeted Oncology, 5(3):175-181.

Wick, W; Roth, P; Wick, A; Weller, M (2010). Was gibt es Neues in der Neuroonkologie. Aktuelle Neurologie, 37(9):454-460.

Weller, M (2010). ZNS-Tumoren. In: Petrasch, S; Ehninger, G. Colloquium Onkologie 10 - Update Hämatologie/Onkologie 2010. München: Lukon, 555-68.

Bürk, K; Farecki, M L; Lamprecht, G; Roth, G; Decker, P; Weller, M; Rammensee, H G; Oertel, W (2009). Neurological symptoms in patients with biopsy proven celiac disease. Movement Disorders, 24(16):2358-2362.

Weller, M; Felsberg, J; Hartmann, C; Berger, H; Steinbach, J P; Schramm, J; Westphal, M; Schackert, G; Simon, M; Tonn, J C; Heese, O; Krex, D; Nikkhah, G; Pietsch, T; Wiestler, O; Reifenberger, G; von Deimling, A; Loeffler, M (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of Clinical Oncology, 27(34):5743-5750.

Weller, M; Stupp, R (2009). Approval of new drugs for glioblastoma. Current Opinion in Neurology, 22(6):617-618.

Wick, W; Weller, M (2009). Classification and management of anaplastic gliomas. Current Opinion in Neurology, 22(6):650-656.

Wick, W; Hartmann, C; Engel, C; Stoffels, M; Felsberg, J; Stockhammer, F; Sabel, M C; Koeppen, S; Ketter, R; Meyermann, R; Rapp, M; Meisner, C; Kortmann, R D; Pietsch, T; Wiestler, O D; Ernemann, U; Bamberg, M; Reifenberger, G; von Deimling, A; Weller, M (2009). NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 27(32):5874-5880.

Hofer, S; Kollias, S; Weller, M (2009). Evolution of glioblastoma. Acta Oncologica, 48(4):630-631.

Mittelbronn, M; Harter, P; Warth, A; Lupescu, A; Schilbach, K; Vollmann, H; Capper, D; Frei, K; Bertalanffy, H; Weller, M; Meyermann, R; Lang, F; Simon, P (2009). EGR-1 is regulated by N-methyl-D-aspartate-receptor stimulation and associated with patient survival in human high grade astrocytomas. Brain Pathology, 19(2):195-204.

Weller, M; Aguzzi, A (2009). Movement disorders reveal Creutzfeldt-Jakob disease. Nature Reviews. Neurology, 5(4):185-186.

Glas, M; Happold, C; Rieger, J; Wiewrodt, D; Bähr, O; Steinbach, J P; Wick, W; Kortmann, R; Reifenberger, G; Weller, M; Herrlinger, U (2009). Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. Journal of Clinical Oncology, 27(8):1257-1261.

Wick, W; Weller, M (2009). Adjuvant therapy. In: Von Deimling, A. Gliomas. Berlin Heidelberg: Springer, 141-153.

Ronellenfitsch, M W; Brucker, D P; Burger, M C; Wolking, S; Tritschler, F; Rieger, J; Wick, W; Weller, M; Steinbach, J P (2009). Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain: A Journal of Neurology, 132(Pt 6):1509-1522.

Gramatzki, D; Pantazis, G; Schittenhelm, J; Tabatabai, G; Köhle, C; Wick, W; Schwarz, M; Weller, M; Tritschler, I (2009). Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene, 28(28):2593-2605.

Dumitru, C A; Weller, M; Gulbins, E (2009). Ceramide metabolism determines glioma cell resistance to chemotherapy. Journal of Cellular Physiology, 221(3):688-695.

Maurer, G D; Tritschler, I; Adams, B; Tabatabai, G; Wick, W; Stupp, R; Weller, M (2009). Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-Oncology, 11(6):747-756.

Roth, P; Weller, M (2009). Comments : Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurgical Review, 32(3):273.

Roth, T; Sokolov, A N; Messias, A; Roth, P; Weller, M; Trauzettel-Klosinski, S (2009). Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. Neurology, 72(4):324-331.

Schittenhelm, J; Beschorner, R; Simon, P; Tabatabai, G; Herrmann, C; Schlaszus, H; Capper, D; Weller, M; Meyermann, R; Mittelbronn, M (2009). Diagnostic value of WT1 in neuroepithelial tumours. Neuropathology and Applied Neurobiology, 35(1):69-81.

Stupp, R; Hegi, M E; Mason, W P; van den Bent, M J; Taphoorn, M J B; Janzer, R C; Ludwin, S K; Allgeier, A; Fisher, B; Belanger, K; Hau, P; Brandes, A A; Gijtenbeek, J; Marosi, C; Vecht, C J; Mokhtari, K; Wesseling, P; Villa, S; Eisenhauer, E; Gorlia, T; Weller, M; Lacombe, D; Cairncross, J G; Mirimanoff, R O (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5):459-466.

Semmler, A; Bao, X; Cao, G; Köhler, W; Weller, M; Aubourg, P; Linnebank, M (2009). Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. Journal of Neurology, 256(8):1277-1280.

Weller, M; Tonn, J C; Ernemann, U; Wiestler, O D; Bamberg, M (2009). Glioblastome : Aktuelle Standards bei Diagnostik und Therapie. Best Practice Onkologie, 4(2):4-11.

Weller, M (2009). Gliomas. In: Lang, F. Encyclopedia of Molecular Mechanisms of Disease. Berlin: Springer, 704-705.

Weller, M; Schlegel, U; Schackert, G (2009). Hirnmetastasen und Meningeosis neoplastica. In: Domschke, W; Berger, M; Hohenberger, W; Meinertz, T. Therapie-Handbuch. München: Elsevier, Urban & Fischer, P3-1.

Diener, H C; Hartung, H P; Bien, C G; Hacke, W; Ringelstein, E B; Ludolph, A; Deuschl, G; Wiltfang, J; Weller, M; Steinhausen, K; Stemper, B; Klatt, J; Drepper, J; Griewing, B; Meier, U; Herschel, M; Hummel, K; Paar, W D; Dintsios, C M; Schade-Brittinger, C; Weber, R; Weimar, C (2009). Klinische Studien in der Neurologie in Deutschland 2008. Aktuelle Neurologie, 36(1):8-18.

Dumitru, C A; Sandalcioglu, I E; Wagner, M; Weller, M; Gulbins, E (2009). Lysosomal ceramide mediates gemcitabine-induced death of glioma cells. Journal of Molecular Medicine, 87(11):1123-1132.

Tritschler, I; Gramatzki, D; Capper, D; Mittelbronn, M; Meyermann, R; Saharinen, J; Wick, W; Keski-Oja, J; Weller, M (2009). Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. International Journal of Cancer, 125(3):530-540.

Weller, M; Kornhuber, J (2009). Neuroleptic malignant syndrome. In: Lang, F. Encyclopedia of Molecular Mechanisms of Disease. Berlin: Springer, 1457.

Schlegel, U; Weller, M; Westphal, M (2009). Neuroonkologische Therapie. Stuttgart: Kohlhammer.

Wick, W; Platten, M; Weller, M (2009). New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology, 11(1):69-79.

Wick, A; Pascher, C; Wick, W; Jauch, T; Weller, M; Bogdahn, U; Hau, P (2009). Rechallenge with temozolomide in patients with recurrent gliomas. Journal of Neurology, 256(5):734-741.

Roth, P; Kissel, M; Herrmann, C; Eisele, G; Leban, J; Weller, M; Schmidt, F (2009). SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. Clinical Cancer Research, 15(21):6609-6618.

Luft, A R; Weller, M (2009). Schlaganfall. Praxis, 98(22):1285-1291.

Luft, A R; Weller, M (2009). Schlaganfall: Plötzlicher Beginn einer langen Odyssee. VSAO Journal, (5):25-7.

Semmler, A; Moskau, S; Stoffel-Wagner, B; Weller, M; Linnebank, M (2009). The effect of MTHFR c.677C>T on plasma homocysteine levels depends on health, age and smoking. Clinical and Investigative Medicine, 32(6):E310-E314.

Opitz, C A; Litzenburger, U M; Lutz, C; Lanz, T V; Tritschler, I; Köppel, A; Tolosa, E; Hoberg, M; Anderl, J; Aicher, W K; Weller, M; Wick, W; Platten, M (2009). Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells, 27(4):909-919.

Hartmann, C; Meyer, J; Balss, J; Capper, D; Mueller, W; Christians, A; Felsberg, J; Wolter, M; Mawrin, C; Wick, W; Weller, M; Herold-Mende, C; Unterberg, A; Jeuken, J W M; Wesseling, P; Reifenberger, G; von Deimling, A (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 118(4):469-474.

Bähr, O; Herrlinger, U; Weller, M; Steinbach, J P (2009). Very late relapses in glioblastoma long-term survivors. Journal of Neurology, 256(10):1756-1758.

Weller, M; Reardon, D; Nabors, B; Stupp, R (2009). Will integrin inhibitors have proangiogenic effects in the clinic? Nature Medicine, 15(7):726; author reply 727.

Strelau, J; Schmeer, C; Peterziel, H; Sackmann, T; Herold-Mende, C; Steinert, H; Weller, M; Unsicker, K (2008). Expression and putative functions of GDF-15, a member of the TGF-β superfamily, in human glioma and glioblastoma cell lines. Cancer Letters, 270(1):30-39.

Kurzwelly, D; Müller, C A; Korfel, A; Thiel, E; Linnebank, M; Weller, M; Herrlinger, U (2008). Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients. Journal of Neuro-Oncology, 90(1):53-55.

Semmler, A; Köhler, W; Jung, H H; Weller, M; Linnebank, M (2008). Therapy of X-linked adrenoleukodystrophy. Expert Review of Neurotherapeutics, 8(9):1367-1379.

Rieger, J; Lemke, D; Maurer, G; Weiler, M; Frank, B; Tabatabai, G; Weller, M; Wick, W (2008). Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. Journal of Neurochemistry, 106(6):2436-2448.

Sarkaria, J N; Kitange, G J; James, C D; Plummer, R; Calvert, H; Weller, M; Wick, W (2008). Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clinical Cancer Research, 14(10):2900-2908.

Teichgräber, V; Ulrich, M; Endlich, N; Riethmüller, J; Wilker, B; De Oliveira-Munding, C C; van Heeckeren, A M; Barr, M L; von Kürthy, G; Schmid, K W; Weller, M; Tümmler, B; Lang, F; Grassme, H; Döring, G; Gulbins, E (2008). Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nature Medicine, 14(4):382-391.

Waerzeggers, Y; Klein, M; Miletic, H; Himmelreich, U; Li, H; Monfared, P; Herrlinger, U; Hoehn, M; Coenen, H H; Weller, M; Winkeler, A; Jacobs, A H (2008). Multimodal imaging of neural progenitor cell fate in rodents. Molecular Imaging, 7(2):77-91.

Schittenhelm, J; Reifenberger, G; Ritz, R; Nägele, T; Weller, M; Pantazis, G; Capper, D; Beschorner, R; Meyermann, R; Mittelbronn, M (2008). Primary anaplastic ganglioglioma with a small-cell glioblastoma component. Clinical Neuropathology, 27(2):91-95.

Wick, W; Stupp, P; Beule, A C; Bromberg, J; Wick, A; Ernemann, U; Platten, M; Marosi, C; Mason, W P; van den Bent, M; Weller, M; Rorden, C; Karnath, H O (2008). A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 10(6):1019-1024.

Happold, C; Ernemann, U; Roth, P; Wick, W; Weller, M; Schmidt, F (2008). Anticoagulation for radiation-induced neurotoxicity revisited. Journal of Neuro-Oncology, 90(3):357-362.

Weller, M; Yung, W K A (2008). Bevacizumab--news from the fast lane? Neuro-Oncology, 10(5):647.

Weller, M (2008). Chemotherapie von Hirntumoren bei Erwachsenen. Der Nervenarzt, 79(2):231-241.

Hegi, M E; Liu, L; Herman, J G; Stupp, R; Wick, W; Weller, M; Mehta, M P; Gilbert, M R (2008). Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. Journal of Clinical Oncology, 26(25):4189-4199.

Weller, M (2008). Hirntumoren. In: Bäumer, R; Maiwald, A. Onkologische Pflege. Stuttgart: Thieme, 301-305.

Weller, M; Schlegel, U (2008). Hirntumoren. In: Schwab, S; Schellinger, P; Werner, C; Unterberg, A; Hacke, W. NeuroIntensiv. Heidelberg: Springer, 577-588.

Broetz, D; Hahn, U; Maschke, E; Wick, W; Kueker, W; Weller, M (2008). Lumbar disk prolapse: response to mechanical physiotherapy in the absence of changes in magnetic resonance imaging. Report of 11 cases. NeuroRehabilitation, 23(3):289-294.

Eisele, G; Roth, P; Wick, W; Weller, M (2008). MGMT in der klinischen Praxis. Onkologie Heute, 6(4):32-39.

Krockenberger, M; Dombrowski, Y; Weidler, C; Ossadnik, M; Hönig, A; Häusler, S; Voigt, H; Becker, J C; Leng, L; Steinle, A; Weller, M; Bucala, R; Dietl, J; Wischhusen, J (2008). Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. Journal of Immunology, 180(11):7338-7348.

Fischer, L; Martus, P; Weller, M; Klasen, H A; Rohden, B; Röth, A; Storek, B; Hummel, M; Nägele, T; Thiel, E; Korfel, A (2008). Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology, 71(14):1102-1108.

Gorlia, T; van den Bent, M J; Hegi, M E; Mirimanoff, R O; Weller, M; Cairncross, J G; Eisenhauer, E; Belanger, K; Brandes, A A; Allgeier, A; Lacombe, D; Stupp, R (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, 9(1):29-38.

Glas, M; Rasch, K; Wiewrodt, D; Weller, M; Herrlinger, U (2008). Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology, 75(3-4):182-185.

Tabatabai, G; Herrmann, C; von Kürthy, G; Mittelbronn, M; Grau, S; Frank, B; Möhle, R; Weller, M; Wick, W (2008). VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. Brain: A Journal of Neurology, 131(10):2579-2595.

Wiendl, H; Feger, U; Mittelbronn, M; Jack, C; Schreiner, B; Stadelmann, C; Antel, J; Brueck, W; Meyermann, R; Bar-Or, A; Kieseier, B C; Weller, M (2005). Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain: A Journal of Neurology, 128(Pt 11):2689-2704.

Mitsdoerffer, M; Schreiner, B; Kieseier, B C; Neuhaus, O; Dichgans, J; Hartung, H P; Weller, M; Wiendl, H (2005). Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. Journal of Neuroimmunology, 159(1-2):155-164.

Schreiner, B; Mitsdoerffer, M; Kieseier, B C; Chen, L; Hartung, H P; Weller, M; Wiendl, H (2004). Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Journal of Neuroimmunology, 155(1-2):172-182.

Weissert, R; Wiendl, H; Pfrommer, H; Storch, M K; Schreiner, B; Barth, S; Seifert, T; Melms, A; Dichgans, J; Weller, M (2003). Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. Journal of Neuroimmunology, 144(1-2):28-37.

Wintterle, S; Schreiner, B; Mitsdoerffer, M; Schneider, D; Chen, L; Meyermann, R; Weller, M; Wiendl, H (2003). Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 63(21):7462-7467.

Schreiner, B; Wischhusen, J; Mitsdoerffer, M; Schneider, D; Bornemann, A; Melms, A; Tolosa, E; Weller, M; Wiendl, H (2003). Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia, 44(3):296-301.

Wischhusen, J; Jung, G; Radovanovic, I; Beier, C; Steinbach, J P; Rimner, A; Huang, H; Schulz, J B; Ohgaki, H; Aguzzi, A; Rammensee, H G; Weller, M (2002). Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Research, 62(9):2592-2599.

Pohl, U; Wick, W; Weissenberger, J; Steinbach, J P; Dichgans, J; Aguzzi, A; Weller, M (1999). Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. International Journal of Oncology, 15(4):829-834.

Weller, M; Malipiero, U; Aguzzi, A; Reed, J C; Fontana, A (1995). Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. Journal of Clinical Investigation, 95(6):2633-2643.

This list was generated on Sat Jul 22 15:20:13 2017 CEST.